NewsBenzinga허치메드, FDA가 1차 면역성 혈소판감소증 치료제 소블레플레닙에 희귀의약품 지정 부여···미국 시장 7년 독점권 획득 자격 부여 허치메드, FDA가 1차 면역성 혈소판감소증 치료제 소블레플레닙에 희귀의약품 지정 부여···미국 시장 7년 독점권 획득 자격 부여 Benzinga 2026.10.29 06:54 (GMT+0) Open on Benzinga Other news BBVA Q3 Adj. EPS $0.61 Misses $0.62 Estimate, Sales $12.560B Miss $12.580B Estimate MSFT Stock Eyes Best Day In Over 3 Months After Earnings Beat — Gene Munster Says 'Software Is Alive And Well, At Least For Now' ING Groep Q3 EPS $0.75 Misses $0.79 Estimate, Sales $7.167B Beat $7.000B Estimate Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B Takeda Pharmaceutical Q2 Adj. EPS $0.48 Beats $0.31 Estimate, Sales $7.457B Beat $7.190B Estimate Takeda Pharmaceutical Co Raises FY2026 GAAP EPS Guidance from JPY 104 to JPY 131
MSFT Stock Eyes Best Day In Over 3 Months After Earnings Beat — Gene Munster Says 'Software Is Alive And Well, At Least For Now'
Takeda Pharmaceutical Co Raises FY2026 Core EPS Guidance from JPY 472 to JPY 482; Raises FY2026 Revenue Guidance from JPY 4,640B to JPY 4,700B
